Investigating how lactate affects pulmonary arterial hypertension
LDHA-lactate signaling in pulmonary arterial hypertension
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA AT DAVIS · NIH-10993634
This study is looking at how a substance called lactate affects the cells in the lungs of people with pulmonary arterial hypertension (PAH), with the hope of finding new ways to treat this condition and help patients feel better.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA AT DAVIS (nih funded) |
| Locations | 1 site (DAVIS, UNITED STATES) |
| Trial ID | NIH-10993634 on ClinicalTrials.gov |
What this research studies
This research focuses on pulmonary arterial hypertension (PAH), a serious condition characterized by high blood pressure in the lungs that can lead to heart failure. The study aims to understand how lactate, a byproduct of metabolism, influences the behavior of cells in the pulmonary arteries, particularly how it promotes cell growth and resistance to cell death. By examining the mechanisms behind this process, the research seeks to identify potential therapeutic targets that could help manage or treat PAH. Patients may benefit from insights that could lead to new treatments aimed at reducing the progression of this disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension.
Not a fit: Patients with other forms of pulmonary hypertension or those without a diagnosis of pulmonary arterial hypertension may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that slow down or reverse the progression of pulmonary arterial hypertension.
How similar studies have performed: Other research has shown promising results in targeting metabolic pathways in similar conditions, suggesting that this approach could be effective.
Where this research is happening
DAVIS, UNITED STATES
- UNIVERSITY OF CALIFORNIA AT DAVIS — DAVIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GONCHAROVA, ELENA — UNIVERSITY OF CALIFORNIA AT DAVIS
- Study coordinator: GONCHAROVA, ELENA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy, cancer cell, cancer microenvironment, cancer progression, cancer therapy